ATHE ATHE
Company Profile ↓Company Overview
ATHE (ATHE) is a publicly traded company listed on with a market capitalization of $797.73M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.37.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR 1.8%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | 1.81% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -15.15% |
| 6 Months: | +44.70% |
| 3 Months: | -3.53% |
| 1 Month: | -20.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)39.39 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 25.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 15.14M | 14.37M | 19.40M | 12.33M |
| Operating Income | -15.14M | -14.37M | -19.40M | -12.33M |
| EBITDA | -15.08M | -14.27M | -19.25M | -12.19M |
| Interest Expense | - | - | - | - |
| Pretax Income | -12.78M | -13.70M | -19.08M | -12.08M |
| Tax Provision | 70.01K | 104.46K | 46.09K | 68.06K |
| Net Income | -12.85M | -13.81M | -19.12M | -12.15M |
| Diluted EPS | -3.18 | -3.42 | -3.12 | -1.14 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | 41.36M | 27.32M | 19.22M | 46.03M |
| Current Assets | 41.14M | 27.05M | 19.04M | 45.87M |
| Cash & Equivalents | 34.81M | 15.77M | 12.64M | 33.16M |
| Inventory | - | - | - | - |
| Receivables | 0 | 65.23K | 0 | - |
| Total Liabilities | 5.89M | 4.50M | 5.43M | 3.62M |
| Current Liabilities | 5.82M | 4.38M | 5.37M | 3.53M |
| Long Term Debt | - | - | - | - |
| Total Debt | 117.49K | 210.38K | 159.04K | 155.46K |
| Total Equity | 35.47M | 22.81M | 13.80M | 42.40M |
| Shares Outstanding | 48.14M | 48.80M | 104.90M | 182.55M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -12.34M | -20.04M | -12.61M | -11.45M |
| Investing Cash Flow | -89.15K | -36.46K | -5.72K | -7.50M |
| Financing Cash Flow | 16.30M | 124.34K | 9.22M | 39.67M |
| Capital Expenditure | -89.15K | -7.31K | -5.72K | - |
| Free Cash Flow | -12.43M | -20.04M | -12.61M | -11.45M |
| Net Change in Cash | 3.88M | -19.95M | -3.40M | 20.72M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | -36.2% | -60.5% | -138.6% | -28.6% |
| ROCE % | -42.6% | -62.6% | -140.1% | -29.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Twin Lakes Capital Management, LLC | 0.77% | 139.26K | $608.56K |
| 2 | Greenleaf Trust | 0.34% | 62.00K | $270.94K |
| 3 | Morgan Stanley | 0.32% | 58.38K | $255.13K |
| 4 | HB Wealth Management, LLC | 0.32% | 58.46K | $255.47K |
| 5 | Citadel Advisors Llc | 0.11% | 20.08K | $87.74K |
| 6 | BNP Paribas Financial Markets | 0.04% | 6.81K | $29.75K |
| 7 | Rhumbline Advisers | 0.01% | 1.97K | $8.61K |
| 8 | Acadian Asset Management. LLC | 0.01% | 1.86K | $8.14K |
| 9 | Gamma Investing LLC | 0.01% | 2.31K | $10.09K |
| 10 | Osaic Holdings Inc. | - | 68 | $297 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATHE
[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQYXhQUUx2VjdLTHh5eHJiWnpBVmVPVU1SdjJXNk9XX0I3VXdZWUg3b1Q3bnl2bk1pQ3h0UGMxVDVMSUNqbWFrRlpBV1hIdW14U0xLd0tkb09TbTRkWHRsVFEtNFpsY2ZOZHFkM0pkUVlLUTVIUHlNUVJ4QzBNNzUxNWIxalozRVNDMHhwZG…
Europe's STOXX 600 closes at record high as earnings, tech gains lift sentiment - Reuters
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNeUZFbTJydmNONDdBVHNVNWJNRXN4X01QRmxzM1hDY25ZTDJWODQtMWpBZ2llZlBfRmFXXzVXaEQtenZrMVFjQS1BQm96djVlMnpXUndVN3N2NlhlOWhOX01JX3d2OWVSZXVoVU5iUGp0WUJkMWtSWVdZTTVDalAxSDJ6R185N2Roa3NDUX…
The German share price index DAX graph is pictured at the stock exchange in Frankfurt - The Lufkin Daily News
<a href="https://news.google.com/rss/articles/CBMikAJBVV95cUxPeVZyb28xLXJFTW82ck5pYU5mNnhoUDJJLUpVVl9vYnVKRDlMOUhCU2JlM3FIWTlqQXBlZVpPQXo1UDVnOUo5NEJKaGRwd2pyaFEzUjJzLVZ0YmlhR3RQTzlmRW5pRkhsUzVHLXViWXltM3FwMEU4QUlfUWJ6SVFWTm4teXRoZGVUSW1EeV…
Alterity CEO to Host 1-on-1 U.S. Investor Meetings - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQeEdOS3BiUW4zSzU3a1poSm9FaUtHSDBlYkhsOUJJeF9icHM5VU5ieEtFUHB4blFWbFNJdDdiY294NFVwQ1p2Z1U2azJVSGItaXNBVHlxR19BclZLQ0hIUXpqMjZxTHNXUzNVZm1yZ1VYRmRZRUdmY1lYSnJNMGV0SkZxeW0tMnQ5UndtTV…
Alterity Therapeutics CEO to Engage U.S. Investors at BTIG Biotechnology Conference 2026 - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMihAJBVV95cUxQZzlBOFBZSXBqU1loX3IteVQ5TzNuOWJvWTdNU3hVRFVYXzBiZlNiN1pNWmdlY0FVN21VcDVXRks0RUp6SlE1V1pCajRjekY3Uk5Jb0NqZVpYVUVRLTVUdmllWGxPeWE0RklpbzltbXd6ZGJpWFlmQTBfVFJLdk9QblNqNHVmalZDQkFlbD…
Alterity’s ATH434 Trial for Rare MSA May Enroll 200 Patients - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOU3V2VnZqVUNrN3JZSkx6N0ZxUWRnWVhmb0p6ZHV6c2RrZWtCbUNvU1ZUbjdDSVBTb0ZiSHphMjlFYUltbXd2eC1MWTRWWHp0ZG8yMk9OMGlvd3lpekZjeDE5bUFqVGhhcGJhZzhCbi1qM0swRmdFVnpzQXBsMkFZVlVyTy15QkdRZlZXOG…
ATHE — Frequently Asked Questions
What is the current share price of ATHE?
As of 2026-08-05 17:25 PDT, ATHE trades at $4.37 on NASDAQ/NYSE. Its 52-week range is $2.92 to $5.89.
What is the market capitalisation of ATHE?
ATHE has a market capitalisation of $797.73M on NASDAQ/NYSE.
What is the P/E ratio of ATHE?
ATHE trades at a trailing price-to-earnings (P/E) ratio of -3.83. Its price-to-book (P/B) ratio is 18.81.
What is the return on equity (ROE) of ATHE?
ATHE has a return on equity (ROE) of -28.65%. Its return on capital employed (ROCE) is -29.03%.
Is ATHE a good stock to buy?
This page provides a data-driven analysis of ATHE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.